AU690371B2 - Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor - Google Patents

Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor

Info

Publication number
AU690371B2
AU690371B2 AU38864/95A AU3886495A AU690371B2 AU 690371 B2 AU690371 B2 AU 690371B2 AU 38864/95 A AU38864/95 A AU 38864/95A AU 3886495 A AU3886495 A AU 3886495A AU 690371 B2 AU690371 B2 AU 690371B2
Authority
AU
Australia
Prior art keywords
gag
ctg
gaa
leu
aag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU38864/95A
Other languages
English (en)
Other versions
AU3886495A (en
Inventor
Thierry Boon-Falleur
Benoit Van Den Eynde
Pierre Van Der Bruggen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of AU3886495A publication Critical patent/AU3886495A/en
Application granted granted Critical
Publication of AU690371B2 publication Critical patent/AU690371B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001178Tumor rejection antigen precursor [TRAP]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/5555Muramyl dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU38864/95A 1994-09-30 1995-09-27 Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor Ceased AU690371B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31596194A 1994-09-30 1994-09-30
US315961 1994-09-30
PCT/US1995/012463 WO1996010413A1 (fr) 1994-09-30 1995-09-27 Compositions contenant des precurseurs d'antigenes de rejet de tumeurs ou des antigenes de rejet de tumeurs, et un adjuvant et/ou un facteur de croissance

Publications (2)

Publication Number Publication Date
AU3886495A AU3886495A (en) 1996-04-26
AU690371B2 true AU690371B2 (en) 1998-04-23

Family

ID=23226857

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38864/95A Ceased AU690371B2 (en) 1994-09-30 1995-09-27 Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor

Country Status (7)

Country Link
EP (1) EP0782453A1 (fr)
JP (1) JPH10511639A (fr)
CN (1) CN1159759A (fr)
AU (1) AU690371B2 (fr)
CA (1) CA2201327A1 (fr)
WO (1) WO1996010413A1 (fr)
ZA (1) ZA958229B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6328971B1 (en) * 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US20060029653A1 (en) 1997-01-29 2006-02-09 Cronk Peter J Therapeutic delivery system
WO1999004265A2 (fr) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Acides nucleiques et polypeptides associes au cancer
CA2584482C (fr) * 1998-02-05 2012-03-27 Smithkline Beecham Biologicals S.A. Derives antigenes associes aux tumeurs de la famille mage, et sequences d'acides nucleiques codant ces derives, utilises pour la preparaiton de proteines de fusion et de compositions destinees a la vaccination
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
GB9826143D0 (en) * 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
KR20090050090A (ko) 2006-08-30 2009-05-19 데이비드 윌리엄 스미스 압출된 재료에 단축 또는 다축 강성을 제공하는 방법 및 이방법을 이용하여 제조된 제품

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5462871A (en) * 1992-08-31 1995-10-31 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode MAGE derived nonapeptides

Also Published As

Publication number Publication date
JPH10511639A (ja) 1998-11-10
ZA958229B (en) 1996-04-24
CA2201327A1 (fr) 1996-04-11
AU3886495A (en) 1996-04-26
CN1159759A (zh) 1997-09-17
WO1996010413A1 (fr) 1996-04-11
EP0782453A1 (fr) 1997-07-09

Similar Documents

Publication Publication Date Title
US6599699B1 (en) Methods for diagnosing a disorder by assaying for MAGE-3
FI117555B (fi) Kasvaimen hyljintäantigeenin esiasteet, kasvaimen hyljintäantigeenit ja niiden käytöt
AU698310B2 (en) Determination of cancerous conditions by mage gene expression
JP3799483B2 (ja) ガン関連抗原をコードする単離核酸分子、その抗原、およびそれらの利用方法
EP0752876B1 (fr) Anticorps monoclonaux qui se fixent a un precurseur de l'antigene de rejet de tumeurs et qui est du type mage-1, mage-1 produit par recombinaison ou un peptide immunogene derive de mage-1
EP1103564B1 (fr) Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1
US7291335B2 (en) Isolated nucleic acid molecules encoding ESO-1 peptides and uses thereof
US5925729A (en) Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
AU690371B2 (en) Compositions containing tumor rejection antigen precursors or tumor rejection antigens, and an adjuvant and/or growth factor
WO1999053938A1 (fr) Peptides isoles correspondant a des sequences d'acides amines de ny-eso-1 qui se lient a des molecules mhc de classe i et mhc de classe ii, et leurs utilisations
US6498021B1 (en) Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-8 and uses thereof
AU664560B2 (en) Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US8142786B2 (en) Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein
IE84173B1 (en) Tumor rejection antigen precursors, tumor rejection antigens and uses thereof